Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Pliant Therapeutics appointed Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA), tasking him with advancing the company's integrin-mediated delivery platform. Blanchette joined from Switch Therapeutics, where he was CSO, and previously led protein chemistry and oligonucleotide delivery strategy at Genentech, bringing over two decades of RNAi and drug-delivery experience.
Key figures
- Vesting
- 4 years; 25% at one-year anniversary, remainder in 36 monthly installments
- Inducement grant options
- 300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.